ABBOTT INDIA LIMITED

Abbott launches AVEIR™ VR leadless pacemaker in India for treating slow heart rhythms.

Abbott's 'Advancing Diversity in Clinical Trials' paper, published in TIME Magazine, highlights four barriers to clinical trial access: lack of trust, transparency, access, and common language. Recommendations include inclusive hiring, educational campaigns, at-home devices, and multi-lingual materials. New partnerships with CISCRP and National Blood Clot Alliance aim to enhance diversity in clinical trials.

Abbott launches AVEIR VR leadless pacemaker in India, approved by CDSCO and FDA. Implanted via catheter from groin, it offers unique mapping, longer battery life, and retrievability, aiming to advance treatment for slow heart rhythms.

Abbott's 'Advancing Diversity in Clinical Trials' paper, published in TIME Magazine, identifies four barriers to clinical trial access: lack of trust, transparency, access, and common language. Recommendations include inclusive hiring, educational campaigns, at-home data logging, and multi-lingual materials. Abbott has expanded its Diversity in Clinical Trials program with new partnerships and a website for clinical trial education. A pilot program with the National Blood Clot Alliance aims to optimize study logistics through a diverse Patient Advisory Panel. Abbott's Diversity in Research Office ensures internal tools and training prioritize diversity, with a cross-divisional diversity data collection tool. By 2023, Abbott's clinical trial participation closely aligns with U.S. census data, and the company has awarded nearly 150 scholarships to increase diversity in healthcare leadership.

Abbott's third-year report, Advancing Diversity in Clinical Trials, outlines strategies to address barriers like trust, transparency, access, and language. It features insights from nearly 100 experts and includes actionable recommendations such as diverse research teams and multilingual resources. Abbott also announced new partnerships and initiatives, including a pilot program with the National Blood Clot Alliance and a Patient Advisory Panel. The company has proactively implemented diversity measures ahead of FDA requirements, aiming to reshape clinical research for underrepresented communities.

Abbott announced new data supporting its Amplatzer Amulet LAA occluder system, showing benefits in treating AFib patients at risk of stroke. Five-year data demonstrates Amulet helps more patients avoid long-term blood-thinning medication compared to Boston Scientific’s Watchman device. The study, presented at AHA’s Scientific Sessions 2024, highlights Amulet’s long-lasting outcomes, effective LAA closure, and reduced need for blood-thinning medication.

In part 2 of the interview with Jennifer Cowger, MD, co-PI of the Abbott TEAM-HF trial, she discusses the trial's unique aspects, emphasizing ongoing patient education and consent. Cowger highlights the importance of ensuring patients fully understand the trial's risks and benefits, with education provided by various staff members to avoid bias. She also addresses the complexity of trials, stating that while some can be streamlined, high-risk trials like TEAM-HF require thoroughness.

Abbott's 'Advancing Diversity in Clinical Trials' shares strategies to improve diversity in healthcare clinical trials, including inclusive hiring, educational campaigns, at-home devices, and multi-lingual materials. New partnerships aim to break traditional barriers, and internal best practices ensure representation in trial designs.

Linear ablation combined with ethanol infusion via the vein of Marshall (EIVOM) significantly improves freedom from atrial arrhythmia recurrence without antiarrhythmic drugs (70.7% vs 61.5%; hazard ratio, 0.73) in patients with persistent atrial fibrillation (AF) undergoing first-time ablation, according to a randomized clinical trial involving 498 patients.

T.C.-F.Y. advises and speaks for Gilead Sciences. G.L.-H.W. advises AstraZeneca, Gilead Sciences, GlaxoSmithKline, Janssen, Virion Biotherapeutics, speaks for Abbott, AbbVie, Ascletis, Bristol-Myers Squibb, Echosens, Ferring, Gilead Sciences, GlaxoSmithKline, Janssen, Roche, and received a research grant from Gilead Sciences.